Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.